Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 30;17(7):1160.
doi: 10.3390/cancers17071160.

Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets

Francesco Rocco Bertuccio  1   2 , Simone Montini  1   2 , Maria Antonietta Fusco  1   2 , Antonella Di Gennaro  1   2 , Gaetano Sciandrone  1   2 , Francesco Agustoni  1   3 , Giulia Galli  1   3 , Chandra Bortolotto  4   5 , Jessica Saddi  6   7 , Guido Baietto  8 , Giulio Melloni  8 , Gioacchino D'Ambrosio  9 , Angelo Guido Corsico  1   2 , Giulia Maria Stella  1   2
Affiliations
Review

Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets

Francesco Rocco Bertuccio et al. Cancers (Basel). .

Abstract

Background: Pleural mesothelioma (PM) is a rare and highly aggressive cancer which arises from mesothelial layer and primarily linked to asbestos exposure, genetic predispositions, and specific mutations. Despite current treatment modalities, including chemotherapy, antiangiogenic therapy and more recently immunotherapy, the prognosis remains dismal, with a median survival time of 6-18 months.

Objectives: The urgent need for novel therapeutic strategies has prompted research into molecular targets and precision medicine approaches. At present, many potential targets for therapeutic strategies have been identified, and emerging clinical trials are demonstrating certain clinical efficacy.

Methods: This review examines advancements in understanding PM's genetic and epigenetic landscape, signaling pathways, and promising therapeutic targets.

Results: We also discuss the results of recent clinical trials and their potential implications for future treatment paradigms.

Keywords: actionable targets; genetics; personalized medicine; pleural mesothelioma.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
PM novel targets and their localization.
See this image and copyright information in PMC

References

    1. Abbott D.M., Bortolotto C., Benvenuti S., Lancia A., Filippi A.R., Stella G.M. Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge. Cancers. 2020;12:1186. doi: 10.3390/cancers12051186. - DOI - PMC - PubMed
    1. Chen Z., Cai Y., Ou T., Zhou H., Li H., Wang Z., Cai K. Global Burden of Mesothelioma Attributable to Occupational Asbestos Exposure in 204 Countries and Territories: 1990–2019. J. Cancer Res. Clin. Oncol. 2024;150:282. doi: 10.1007/s00432-024-05802-6. - DOI - PMC - PubMed
    1. Allena N., Venkatram S., Diaz-Fuentes G. Malignant Pleural Mesothelioma. In: Strumfa I., Uljanovs R., Strumfs B., editors. Challenges in Pleural Pathology. IntechOpen; Rijeka, Croatia: 2024.
    1. Batirel H.F., Metintas M., Caglar H.B., Ak G., Yumuk P.F., Yildizeli B., Yuksel M. Adoption of Pleurectomy and Decortication for Malignant Mesothelioma Leads to Similar Survival as Extrapleural Pneumonectomy. J. Thorac. Cardiovasc. Surg. 2016;151:478–484. doi: 10.1016/j.jtcvs.2015.09.121. - DOI - PubMed
    1. Treasure T., Lang-Lazdunski L., Waller D., Bliss J.M., Tan C., Entwisle J., Snee M., O’Brien M., Thomas G., Senan S., et al. Extra-Pleural Pneumonectomy versus No Extra-Pleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma: Clinical Outcomes of the Mesothelioma and Radical Surgery (MARS) Randomised Feasibility Study. Lancet Oncol. 2011;12:763–772. doi: 10.1016/S1470-2045(11)70149-8. - DOI - PMC - PubMed

LinkOut - more resources